Learning the Artistry of Startups

Add this event to your calendar:
07/05/2015 13:30 07/05/2015 15:00 America/New_York Learning the Artistry of Startups Café ArtScience , 650 Kendall St , Cambridge , MA 02142 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY
May
7
Event

Learning the Artistry of Startups

Café ArtScience , 650 Kendall St , Cambridge , MA 02142

May 07, 2015 from 13:30 PM to 15:00 PM (EST)

$10 - $35


JLABS BOSTON EVENT Program Overview:
What does it take to be a startup CEO? How do the first moments and early partnerships set the stage for a fundable company and a winning culture?

Join us on May 7th to pick the brain of two successful entrepreneurs and to learn the secret sauce of starting a company. This session will be moderated by Robert Urban, Head of Johnson & Johnson Innovation, Boston.

The Executive Speaker Series provides an intimate forum for biotech experts to share their career successes, challenges and lessons learned throughout their professional adventure to an audience of entrepreneurs getting ready to embark on a similar path. The program is an interactive and inspiring experience, both for the panelists and the audience.

Agenda:
11:30 AM | Registration, Lunch, and Networking
12:00 PM | Presentation, Interview and Q&A
01:00 PM | Program Close

Speakers:
Zoe Barry | Founder & CEO, ZappRx read bio»
Ankit Mahadevia | Entrepreneur in Residence, Atlas Venture read bio»
[moderator] Robert Urban | Head, Johnson & Johnson Innovation, Boston read bio»

Fees:
$35 General Public
$20 Student/Academic
$45 On-site

Location:
Café ArtScience
650 Kendall St
Cambridge, MA 02142

Speakers' Biographies:
Zoe Barry Zoe Barry | Founder & CEO, ZappRx
Zoe Barry is the Founder and CEO of ZappRx, a next generation prescription platform dubbed "The Amazon 1-click meets Turbo Tax mash-up of specialty medication orders."
Zoe launched her career on Wall Street working at the broker-dealer firm DeMatteo Monness and later the hedge fund Dawson Capital. Despite a longstanding flirtation with healthcare (Zoe was nearly pre-med in college, moonlighted as a veterinarian saving Bald Eagles one summer in Alaska, and later worked in a neuroscience primate research lab at Harvard Medical School), Zoe waited until the glory days of Wall Street fully waned before making the leap to the healthcare sector full time.
In 2011 Zoe joined AthenaHealth as her first foray into the industry, but quickly realized the inefficiencies in ePrescribing and left ATHN to launch ZappRx in 2012. ZappRx counts Atlas Venture and SR One as institutional investors; Zoe has raised $10M of capital to date.
Zoe graduated from Columbia University in 2007 with a B.A. in Anthropology and a concentration in History. Zoe was part of the Honors Thesis Seminar, focusing her thesis work on whisky. All of ZappRx's technology sprints are named alphabetically* (like hurricanes) - to date the company is on Inchgower.
Connect with Zoe: Follow on Twitter Connect on LinkedIn


Ankit Mahadevia Ankit Mahadevia | Entrepreneur in Residence, Atlas Venture
Ankit Mahadevia focuses on novel drug discovery platforms, therapeutic products, and other medical technologies that meet a significant unmet clinical need. He is Founder and CEO of Spero Therapeutics, Co-founder and CBO of Rodin Therapeutics, and Co-founder of Synlogic Therapeutics.
Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics. He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS).
Along with his current roles, Ankit serves on the Board of RaNA Therapeutics and was appointed by the Secretary of Health and Human Services as a Council Member for the National Center for Advancement of Translational Sciences of the NIH. Previously, he worked closely with Annovation Therapeutics as Acting CBO (acquired by The Medicines Company), Arteaus Therapeutics as Acting CBO (acquired by Eli Lilly), JenaValve, Nimbus Discovery, and Sirion Therapeutics (acquired by Alcon and Bausch & Lomb).
Connect with Ankit: Follow on Twitter Connect on LinkedIn


Robert Urban Robert Urban | Head, Johnson & Johnson Innovation, Boston
Robert is Head of the Johnson & Johnson Innovation, Boston. He joined the Johnson & Johnson Family of Companies from the Massachusetts Institute of Technology, where he was the founding Executive Director of the Koch Institute for Integrative Cancer Research. In this leadership role, Robert worked to build the Koch Institute into new standard for interdisciplinary disease-focused research via an expanding, highly-effective, relationship network with other academic oncology centers, industrial partners, cancer-focused philanthropists and investors. During Robert's tenure, the Koch Institute launched seventeen start-up companies and its technology was the source of over 50 out-licensing transactions.
Robert was recruited to MIT from Acretia Inc. – a product acquisition and out-licensing company where he was the President and CEO. During his time at Acretia Inc. the organization conducted technical due diligence on more than 280 product opportunities and completed the acquisition of three distinct product lines.
Prior to this, Robert held a variety of business development and clinical development roles in the pharmaceutical industry. He has worked in the areas of oncology, HPV, anti-inflammatory and infectious diseases. His experience includes clinical product development, operations oversight, licensing and acquisitions, capital fund raising, company creation, and building relationships with key thought-leaders.
Robert received his Bachelor of Arts degree in Microbiology and his PhD in Microbiology and Immunology from the University of Texas system, and was an Irvington Fellow in structural immunology at Harvard University.
Connect with Robert: Follow on Twitter Connect on LinkedIn Read the Blog



About the Executive Speaker Series:
The Executive Speaker Series provides an intimate forum for biotech experts to share their career successes, challenges and lessons learned throughout their professional adventure to an audience of entrepreneurs getting ready to embark on a similar path. The program is an interactive and inspiring experience, both for the panelists and the audience.


Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), New York City, and with Shanghai opening in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact


Related content